



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
GENSET.045AUSAPPLICATION NO.
09/416,384INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Blumenfeld et al.FILING DATE
October 12, 1999GROUP
1655

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
✓	1	Blouin J. L. et al., Schizophrenia Susceptibility Loci on Chromosomes 13q32 and 8p21, (1998) Nature Genetics Vol. 20 pgs. 70-73.
	2	Detra-Wadleigh S. D. et al., A High-Density Genome Scan Detects Evidence for a Bipolar-Disorder Susceptibility Locus on 13q32 and Other Potential Loci on 1q32 and 18p11.2, (1999) Proc. Natl. Acad. Sci. USA, vol. 96 pgs. 5604-5609
	3	Li, Shi-Hua et al., Novel Triplet Repeat Containing Genes in Human Brain: Cloning, Expression, and Length Polymorphisms, (1993) Genomics 16:572-579.
	4	GENBANK L10374, Jul 26, 1993.
	5	GENBANK H09867, Jun 23, 1995.
	6	GENBANK H09780, Jun 23, 1995.
	7	GENBANK AA424106, Oct. 16, 1997.
	8	GENBANK AA424056, Oct. 16, 1997.
	9	GENBANK AA319416, Apr 19, 1997.

S:\DOCS\IDOP\IDOP-1689.DOC
040501

EXAMINER	DATE CONSIDERED
	5/12/02

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

#24 FEB 04
TECH CENTER 1600/2900



FEB 04

TECH CENTER 1600/2900

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995; no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/416.384
		Filing Date	October 12, 1999
		First Named Inventor	Blumenfeld, et al.
		Group Art Unit	1655
		Examiner Name	J. Fredman
		Attorney Docket Number	50.US2.REG
Sheet	2	of	2

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
X	B	-& EMBL/GENBANK DATABASES Accession no. L10374 Sequence Reference HSMRNAC; 23 June 1993; XP002134451	
X	C	WANG, ET AL.; "Large-scale identification, mapping and genotyping of single-nucleotide polymorphisms in the human genome"; Science, U.S., American Association for the Advancement of Science, Vol. 280, 1 Jan 1998, pgs. 1077-1082; SP002089398; ISSN: 0036-8075	
3	D	KRUGLYAK, L.; "Passage text. The use of a genetic map of biallelic markers in linkage studies"; Nature Genetics, U.S., New York, NY; Vol. 17, no. 1; 1 Sept. 1997, pgs. 22-24; XP002050647; ISSN: 1061-4036	
4	E	MING-WEI LIN, ET AL.; "Suggestive evidence for linkage of schizophrenia to markers on chromosome 13 in caucasian but not oriental populations"; Human Genetics, DE, Berlin, vol. 99, no. 3, March 1997, pgs. 417-420; XP000876937	
5	F	EMBL/GENBANK DATABASES Accession no. AA989298 Sequence ID AA989298; 27 August 1998; "National Cancer Institute, Cancer Genome Anatomy Project ..."; XP002135005	
6	G	EMBL DATABASE Accession no B75361 Sequence ID B75361; 14 January 1998; ADAMS, et al.; "Use of BAC end sequences for sequence-ready map building"; XP002135179	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.